AIDS 2006 - Immune Based Therapies

Immune Based Therapies

MOAX04

Type:

Oral abstract session

Back

Venue:

Session Room 9

Interpretation:

None

Time:

16:15 - 17:45

Code:

MOAX04

Co-Chairs:

Jonathan Angel, Canada
Matthias Wienold, Germany

Presentations in this session:
16:15
MOAX0401 Immunotherapies for HIV: Where have we been, and where are we going?
Alan Landay, United States
(TBC)
16:30
MOAX0402
Abstract
Powerpoint (982 KB) A single dose of glycosylated recombinant simian IL-7 induces transient T cell homing into lymph nodes, increases peripheral naïve and memory T cell numbers and stimulates thymic function in healthy Rhesus macaques
Presented by Stephanie Beq, France
S. Beq¹, C. Schilte¹, D. Gautier¹, B. Assouline², P. Lavedan³, X. Montagutelli³, M. Brahic¹, R. Cheynier¹
¹Institut Pasteur, Virology, Paris, France, ²Cytheris SA, Issy-les-moulineaux, France, ³Institut Pasteur, Animalerie centrale, Paris, France

16:45
MOAX0403
Abstract Treatment with recombinant human growth hormone (r-hGH) leads to increased thymic output in HIV-Infected subjects with incomplete immune rReconstitution on highly active antiretroviral therapy (HAART)
Presented by Kimberly Smith, United States
K. Smith¹, L. Zheng², R. Bosch², D. Margolis³, A. Tenorio¹, L. Napolitano⁴, R. Pollard⁵, E. Connick⁶, B. Gross⁷, I. Frances⁷, R. Wang², N. Muurahainen⁸, V. Stocker⁹, ACTG 5174 Protocol Team
¹Rush University Medical Center, Section of Infectious Diseases, Chicago, United States, ²Harvard School of Public Health, Statistical and Data Analysis Center, Boston, United States, ³University of North Carolina, Section of Infectious Diseases, Chapel Hill, United States, ⁴University of California at San Francisco, San francisco, United States, ⁵UC Davis Medical Center, Section of Infectious Diseases, Sacramento, United States, ⁶University of Colorado Heath Sciences Center, Denver, United States, ⁷University of Michigan, Ann Arbor, United States, ⁸Serono, Inc, Rockland, United States, ⁹AACTG Operations Center, Silver Spring, United States

17:00
MOAX0404
Abstract Comparing CD4+ T-cell decline during treatment interruption in HIV-1-infected patients who did or did not receive the candidate immunotherapy Vacc-4x
Presented by Maja A. Sommerfelt, Norway
M.A. Sommerfelt¹, F.W.N.M. Wit², J. Nyhus¹, A.-M.B. Kran³, I. Baksaas⁴, J.M.A. Lange², B. Sorensen¹, D. Kvale³
¹Bionor Immuno, Skien, Norway, ²International Antiviral Therapy Evaluation Center (IATEC), Amsterdam, Netherlands, ³Ullevaal University Hospital, Oslo, Norway, ⁴Mericon, Skien, Norway

17:15
MOAX0405
Abstract Safety of VSSP as immunopotentiator in cuban HIV/AIDS patients treated with antiretroviral
Presented by Adriana Carr, Cuba
A. Trujillo¹, D. Abreu², R. Diaz¹, A. Rittoles¹, M.C. Godinez¹, R. Molina¹, Y. Borrero¹, Y. Bebelagua³, D. Garrido¹, T. Rojas¹, A. Urbino¹, T. Serrano¹, D. Cofat¹, O. Calderon¹, F. Nuñez¹, M. Leal¹, A. Gonzalez¹, M. Trueba², A. Carr³, R. Perez⁴, L.E. Fernandez³, J. Perez⁵
¹Tropical Medicine Institute Pedro Kouri (IPK), Clinical, Havana, Cuba, ²Tropical Medicine Institute Pedro Kouri (IPK), Pharmacy, Havana, Cuba, ³Center of Molecular Immunology, Vaccine, Havana, Cuba, ⁴Center of Molecular Immunology, Research Director, Havana, Cuba, ⁵Tropical Medicine Institute Pedro Kouri (IPK), Clinical Director, Havana, Cuba

Audio files:

English audio file (mp3 format, 35.1 MB)

Rapporteur reports

Science Track A: Biology and Pathogenesis of HIV report by Dr. Rupert Kaul

Presentations in session MOAX0401 focused on recent trials of immune therapy in HIV infected individuals. Several immune therapies showed a promising impact on intermediate immune endpoints, such as CD4 counts and thymic output, but further studies are needed to determine their clinical impact.

Stephanie Beq (France) presented data from preclinical trials of glycosylated recombinant simian IL7 in healthy (SIV uninfected) macaques. Therapy was associated with an increase in total CD4 counts, likely due to a combination of increased thymic output, decreased destruction and increased T cell proliferation. IL7 receptor levels decreased transiently after administration, and no anti-IL7 antibodies were detected.

Kimberly Smith (USA) discussed ACTG5174, a trial of two low-dose recombinant Human Growth Hormone (rHGH) regimens, together with HAART, in chronically HIV-infected individuals with CD4<350/mm. Both regimens were associated with short term increases in total CD4, naive CD4 (number and %) and thymic size.

Maria Sommerfelt (Norway) presented data from a phase 2 clinical trial of Vacc-4x, a cocktail of 4 modified p24 peptides antigens administered subdermally in water, together with a GMCSF adjuvant. This was administered together with HAART, and followed by a trial of therapy cessation, with reinitiation on clinical grounds. The two regimens were well tolerated, and some recipients had subsequently remained off HAART for several years, although their viral load was high, and the study had no comparison arm.

Finally, Adrianna Carr (Cuba) presented very early data regarding intermittent administration of VSSP, together with HAART, to chronically HIV-infected individuals. The aim was to block the GM3 ganglioside, a membrane component that may enhance HIV fusion. The product appeared well-tolerated, but no immune or clinical data were presented.

Science Track B: Clinical Research, Treatment and Care report by Dr Schlomo Staszewski

Immune-based therapies are an important field of research, holding promise for the future. Several studies investigating the effect of immune stimulating compounds on HIV-associated immunodeficiency were presented on Monday afternoon.

Stephanie Beq from the Pasteur Institute presented data on an improved formulation of r-sIL-7, which has the potential to increase CD4 cells in macaques through peripheral and thymic proliferation. However its effects are limited by the rapid inactivation of the compound due to the induction of anti – r-sIL7. In contrast glycosylated r-sIL-7 does not induce antibodies and its halflife is increased to 14 hours. In rhesus Macaques glycosylated r-sIL-7 induced a sustained increase of all T cell subsets by increased proliferation (Ki-67) increased survival (Bcl-2) and increased thymic output (sj/bTREC ratio).

A randomized study performed by the AACTG evaluated the immunogenic effects of rGH.

Treatment with rGH and HAART was associated with greater increases in total and naïve CD4 count than treatment with HAART alone. The effect was dose dependant in favour of the higher dosage. Treatment with rGH was associated with an increase in thymus size, associated with an increase in recent thymic emigrants. However, it is unclear if this increase is greater than that observed with HAART alone. Improved LPA responses to recall and neoantigens were not seen following treatment with rGH. Adverse events were infrequent. During the discussion of the data, Smith, the presenting author, insisted that the results of the study should not have consequences fore clinical practice. She emphasized the need for a larger study with higher dosages of rGH to evaluate the functionality of the CD4 cells.

Add this session to your itinerary and back

Back to the Programme-at-a-Glance

The organizers reserve the right to amend the programme.